Cyclooxygenases regulation by estradiol on endothelium

Current Pharmaceutical Design

Volumn 12, Issue 2, 2006, Pages 205-215

  Hermenegildo, Carlos ^a,b,c   Oviedo, P J ^b   Cano, A ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Anti inflammatory drugs; Endothelium dysfunction; Hormone replacement therapy; Prostacyclin; Raloxifene; Thromboxane

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; DICLOFENAC; DIENOGEST; ESTRADIOL; ESTROGEN; ESTRONE; FULVESTRANT; GESTAGEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; PHYTOESTROGEN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RALOXIFENE; ROFECOXIB; TAMOXIFEN; THROMBOXANE A2; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESTROGEN RESPONSIVE ELEMENT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART INFARCTION; HORMONAL REGULATION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IN VITRO STUDY; INFLAMMATION; KIDNEY FAILURE; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHEAR STRESS; SMOKING; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; TRANSCRIPTION REGULATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; ANIMAL; DRUG EFFECT; ENDOTHELIUM; ENZYMOLOGY; METABOLISM;

ANIMALS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM; ESTRADIOL; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS I; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33644853185     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775193136     Document Type: Review

References (129)

1. Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 2001; 7: 1075-85.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Cano A, Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update 2000; 6:207-11.
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
5. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 2002; 38: 89-98.
6. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 2002; 53: 597-604.
7. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002; 105: 1368-73.
8. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36: 1143-58.
9. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of l7beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98: 36-42.
10. Shwaery GT, Vita JA, Keaney JFJ. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 1998; 138: 255-62.
11. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A. Estradiol reduces F2alpha -isoprostane production in cultured human endothelial cells. Am J Physiol Heart Circ Physiol 2002; 283: H2644-H2649.
12. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996; 10: 615-24.
13. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV, Sanz MJ. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res 2002; 91: 1142-50.
14. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80:1832-6.
15. Akishita M, Kozaki K, Eto M, Yoshizumi M, Ishikawa M, Toba K, et al. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun 1998; 251: 17-21.
16. Arnal JF, Gourdy P, Elhage R, Garmy-Susini B, Delmas E, Brouchet L, et al. Estrogens and atherosclerosis. Eur J Endocrinol 2004; 150: 113-7.
17. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002; 89: 12E-8E.
18. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-26.
19. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-19.
20. White RE. Estrogen and vascular function. Vascul Pharmacol 2002; 38: 73-80.
21. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest 2003; 112: 302-7.
22. Ganz P. Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol 2002; 90: F11-F16.
23. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 530: 688-708.
24. Sanz-Gonzalez SM, Cano A, Valverde MA, Hermenegildo C, Andres V. Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 107-22.
25. Herrington DM, Klein KP. Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis 2003; 166: 203-12.
26. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 2003; 23: 11-6.
27. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. Circulation 2004; 109: 672-93.
28. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest 1998; 102: 176-83.
29. Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S. The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm Res 2000; 49: 460-5.
30. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL, et al. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 2002; 26: 610-6.
31. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69: 145-82.
32. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002; 13: 497-504.
33. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89: 26-32.
34. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
35. Davidge ST. Prostaglandin H Synthase and Vascular Function. Circ Res 2001; 89: 650-60.
36. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65: 153-9.
37. Kim JJ, Wang J, Bambra C, Das SK, Dey SK, Fazleabas AT. Expression of cyclooxygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy. Endocrinology 1999; 140: 2672-8.
38. Cheng HF, Harris RC. Cyclooxygenases, the Kidney, and Hypertension. Hypertension 2004; 43: 525-30.
39. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000 49: 367-92.
40. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871-5.
41. Hinz B, Brune K. Cyclooxygenase-2: 10 Years Later. J Pharmacol Exp Ther 2002; 300: 367-75.
42. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
43. Hla T. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. Prostaglandins 1996, 51: 81-5.
44. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 2002; 99: 13371-3.
45. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361: 981-2.
46. DeWitt DL, Day JS, Sonnenburg WK, Smith WL. Concentrations of prostaglandin endoperoxide synthase and prostaglandin 12 synthase in the endothelium and smooth muscle of bovine aorta. J Clin Invest 1983; 72: 1882-8.
47. Doroudi R, Gan LM, Selin Sjogren L, Jern S. Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochem Biophys Res Commun 2000; 269: 257-64.
48. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
49. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999; 50: 661-7.
50. Camacho M, Vila L. Transcellular formation of thromboxane A2 in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I-synthase activity. Thromb Res 2000; 99: 155-64.
51. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146: 591-604.
52. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331.
53. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PG12) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-44.
54. Wolin MS. Interactions of Oxidants With Vascular Signaling Systems. Arterioscler Thromb Vasc Biol 2000; 20: 1430-42.
55. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
56. Mukherjee D, Topol E. Pharmaceutical advertising versus research spending: Are profits more important than patients? Am Heart J 2003; 146: 563-4.
57. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 2003; 21: 1663-7.
58. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
59. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A. et al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 2000; 284: 1247-55.
60. Stiller CO, Hjemdahl P. Endothelial COX-2 inhibition: possible relevance for hypertension and cardiovascular risk? J Hypertens 2003; 21: 1615-8.
61. Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med 2002; 347: 1025-6.
62. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-55.
63. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994; 89: 1943-50.
64. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996; 94: 1402-7.
65. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94: 727-33.
66. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TRJ, Lubahn DB, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997; 3: 545-8.
67. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 1998; 64: 187-91.
68. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002; 90: 1087-92.
69. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, et al. Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor beta. Science 2002; 295: 505-8.
70. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 1997; 349: 1146-7.
71. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004; 69: 537-42.
72. Nadal A, Diaz M, Valverde MA. The estrogen trinity: membrane, cytosolic, and nuclear effects. News Physiol Sci 2001; 16: 251-5.
73. Teoh H, Quan A, Leung SW, Man RY. Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol 2000; 129: 1301-8.
74. Tep-areenan P, Kendall DA, Randall MD. Mechanisms of vasorelaxation to 17[beta]-oestradiol in rat arteries. Eur J Pharmacol 2003; 476: 139-49.
75. Naderali EK, Smith SL, Doyle PJ, Williams G. Vasorelaxant effects of oestradiols on guinea pigs: a role for gender differences. Eur J Clin Invest 2001; 31: 215-20.
76. Salom JB, Burguete MC, Perez-Asensio FJ, Centeno JM, Torregrosa G, Alborch E. Acute relaxant effects of 17-beta-estradiol through non-genomic mechanisms in rabbit carotid artery. Steroids 2002; 67: 339-46.
77. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis 1995; 6: 417-22.
78. Shaw L, Taggart MJ, Austin C. Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br J Pharmacol 2000; 129: 555-65.
79. Montgomery S, Shaw L, Pantelides N, Taggart M, Austin C. Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br J Pharmacol 2003; 139: 1249-53.
80. Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, et al. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. Science 1999; 929-31.
81. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 2000; 97: 5930-5.
82. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, et al. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem 2001; 276: 27071-6.
83. Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, Komesaroff PA. Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J Clin Endocrinol Metab 2002; 87: 5072-5.
84. Bracamonte MP, Rud KS, Miller VM. Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J Cardiovase Pharmacol 2002; 39: 704-13.
85. Myers SI, Turnage RH, Bartula L, Kalley B, Meng Y. Estrogen increases male rat aortic endothelial cell (RAEC) PG12 release. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 403-9.
86. Davidge ST, Baker PN, McLaughlin MK, Roberts JM. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 1995; 77: 274-83.
87. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER. Integration of the Non-genomic and Genomic Actions of Estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 2002; 277: 50768-75.
88. Mikkola T, Ranta V, Orpana A, Ylikorkala O, Viinikka L. Effect of physiological concentrations of estradiol on PGI2 and NO in endothelial cells. Maturitas. 1996; 25: 141-7.
89. Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 2002, 9: 273-81.
90. Vagnoni KE, Magness RR. Estrogen and lipopolysaccharide stimulation of prostacyclin production and the levels of cyclooxygenase and nitric oxide synthase in ovine uterinen arteries. Biol Reprod 1998; 59: 1008-15.
91. Janowiak MA, Magness RR, Habermehl DA, Bird IM. Pregnancy increases ovine uterine artery endothelial cyclooxygenase-1 expression. Endocrinology 1998; 139: 765-71.
92. Habermehl DA, Janowiak MA, Vagnoni KE, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. IV. Cyclooxygenase isoform expression during the ovarian cycle and pregnancy in sheep. Biol Reprod 2000; 62: 781-8.
93. Davidge ST, Zhang Y. Estrogen replacement suppresses a prostaglandin H synthase-dependent vasoconstrictor in rat mesenteric arteries. Circ Res 1998; 83: 388-95.
94. Armstrong SJ, Zhang Y, Stewart KG, Davidge ST. Estrogen replacement reduces PGHS-2-dependent vasoconstriction in the aged rat. Am J Physiol Heart Circ Physiol 2002; 283: H893-H898.
95. Ospina JA, Krause DN, Duckles SP. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 2002; 33: 600-5.
96. Ospina JA, Duckles SP, Krause DN. 17beta-Estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am J Physiol Heart Circ Physiol 2003; 285: H241-H250.
97. O'Sullivan MG, Goodrich JA, Adams MR. Increased prostacyclin synthesis by atherosclerotic arteries from estrogen-treated monkeys. Life Sci 2001; 69: 395-401.
98. Geary GG, McNeill AM, Ospina JA, Krause DN, Korach KS, Duckles SP. Cerebrovascular NOS and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-alpha. J Appl Physiol 2001, 91: 2391-9.
99. Rupnow HL, Phemetton TM, Modrick ML, Wiltbank MC, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VIII. Estrogen and progesterone effects on cPLA2, COX-1, and PGIS protein expression. Biol Reprod 2002; 66: 468-74.
100. Stewart KG, Zhang Y, Davidge ST. Estrogen decreases prostaglandin H synthase products from endothelial cells. J Soc Gynecol Investig 1999; 6: 322-7.
101. Saetrum OO, Duckles SP, Krause DN. Regional differences in the effect of oestrogen on vascular tone in isolated rabbit arteries. Pharmacol Toxicol 2002, 91: 77-82.
102. Seeger H, Mueck AO, Lippert TH. Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci 1999; 65: L167-L170.
103. Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000; 101: 2258-63.
104. Cooke JP. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol 1997; 20: 11-51.
105. Willerson JT, Kereiakes DJ. Endothelial dysfunction. Circulation 2003; 108: 2060-1.
106. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-9.
107. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001: 135: 939-53.
108. Akhrass F, Evans AT, Wang Y, Rich S, Kannan CR, Fogelfeld L, et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 5611-4.
109. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
110. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus Progestin and the Risk of Coronary Heart Disease. N Engl J Med 2003; 349: 523-34.
111. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
112. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-81.
113. Palacios S, Calaf J, Cano A, Parrilla JJ. Relevant results of the WHI study for the management of the menopause in Spain. Maturitas 2003; 44: 83-6.
114. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998; 69: 883-8.
115. Mueck AO, Seeger H, Lippert C, Wallwiener D. Urinary excretion of vasoactive markers following estrogen replacement therapy in postmenopausal women. Int J Clin Pharmacol Ther 2000; 38: 381-6.
116. Mueck AO, Seeger H, Ludtke R, Graser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas 2001; 38: 305-13.
117. Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, et al. Estrogen Plus Progestin and the Risk of Peripheral Arterial Disease: The Women's Health Initiative. Circulation 2004; 109: 620-6.
118. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs: Prospective Results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-101.
119. Seeger H, Mueck AO, Teichmann AT, Lippert TH. Effect of sequential estrogen/progestin treatment on biochemical vasoactive markers in postmenopausal women comparing oral and transdermal application. Clin Exp Obstet Gynecol 2000; 27: 17-20.
120. Viinikka L, Orpana A, Puolakka J, Pyorala T, Ylikorkala O. Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2. Obstet Gynecol 1997; 89: 104-7.
121. Rosano GMC, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection. Maturitas 2003; 46: S17-S29.
122. Mendelsohn ME, Rosano GMC. Hormonal regulation of normal vascular tone in males. Circ Res 2003; 93: 1142-5.
123. Mikkola T, Ranta V, Orpana A, Viinikka L, Ylikorkala O. Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells. Fertil Steril 1996; 66: 389-93.
124. Mikkola T, Viinikka L, Ylikorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000; 73: 72-4.
125. Garcia-Martinez MC, Hermenegildo C, Tarin JJ, Cano A. Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells. Acts Obstet Gynecol Scand 2003; 82: 705-10.
126. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 2004; 11: 430-7.
127. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.
128. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
129. Matz RL, Schott C, Stoclet JC, Andriantsitohaina R. Age-related epdothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. Physiol Res 2000; 49: 11-8.